Cytokinetics ( NASDAQ: CYTK ) announced plans to offer approximately $500 million of shares of its common stock in an underwritten public offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. Source: Press Release More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics CEO Blum says positioned to market heart drug aficamten by itself Cytokinetics names Sung Lee as CFO.